Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients.
Endometrial hyperplasia has since long been proposed to be a predecessor to endometrial carcinoma. In this prospective randomised study one group was treated with abrasio only at regular intervals to follow the natural course. In this group 96/176 were normalised after a 2 year follow-up and 3 patients developed cancer. The frequency of normalised patients after abrasio only (55%) resembles that of cyclic low-dose gestagen treatment. In the other patient group treated with Medroxy progesterone acetate 500 mg i.m. twice weekly for 3 months and then followed for 2 years, 86/89 normalised and none developed cancer.
Lindahl
B
B
Department of Obstetrics and Gynecology, Lund University Hospital, Sweden.
Willén
R
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003475:Curettage; D004717:Endometrium / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery
D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone